Bank of America met with Merck's chief medical officer and maintained its Buy rating with a $166 price target, citing confidence in the drugmaker's pipeline. The meeting focused on sacituzumab tirumotecan, an antibody-drug conjugate being tested in lung cancer, with results expected 25 October at the European Society for Medical Oncology Congress. Merck's Keytruda generated $31.7 billion in 2025 sales but faces US patent expiration starting in 2028. Management claims newer drugs carry over $70 billion in annual revenue potential by the mid-2030s. The chief medical officer dismissed concerns about a failed June trial with rival Gilead Sciences, noting different patient populations. BofA analysts believe pipeline data will drive the stock's next gains, though the $166 target offers modest upside from current levels.

Marriott International has expanded and extended its revolving credit facility through a Seventh Amended and Restated Credit Agreement with Bank of America and other lenders. The agreement, executed on 23 September 2026, increases total commitments from $4.50 billion to $5.00 billion and raises the potential commitment cap to $5.50 billion. The facility's maturity has been extended from 14 December 2027 to 23 September 2031. The revised agreement adjusts interest rate margins, fees, and EBITDA calculations, with pricing tied to Marriott's public debt ratings. The expanded credit facility strengthens Marriott's liquidity position and capital structure, supporting operational needs and strategic initiatives in the global hospitality sector. The company may implement future amendments to reflect environmental performance metrics.